Dr. Andrej Belančić is a (31 years old) Specialist in Clinical Pharmacology at the Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Croatia. He also holds the academic title of Lecturer at the Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, Croatia. In 2024, he was awarded the title of Best Young Scientist at the Faculty of Medicine, University of Rijeka. Dr. Belančić is the author or co-author of approximately 100 scientific and professional full-text articles and about 200 scientific abstracts. He has contributed as an author or co-author to several national guidelines in the field of metabolic diseases, authored multiple book chapters, and served as editor for several books, textbooks, and manuals. His scientific activities primarily focus on clinical pharmacology (treatment outcomes, pharmacoeconomics, pharmacovigilance, clinical trials), obesity and associated metabolic diseases, and rare disease therapeutics. He serves as Co-chair of the Early Career Clinical Pharmacologists Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and is an active member of the Croatian Society for Clinical Pharmacology and Therapeutics of the Croatian Medical Association. He is also an active member of the European Society of Hypertension (ESH) Working Group on Diabetes and Metabolic Risk Factors, and the ESH Working Group on Lifestyle, Cardiovascular Therapy and Adherence. Dr. Belančić is a member of the Croatian Hypertension League, Secretary of the Croatian Society of Obesity of the Croatian Medical Association, and a member of the European Association for the Study of Obesity (EASO) and the World Obesity Federation (WOF). Furthermore, he is an active member of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association.